HOTEL101-MILAN IS SET TO HAVE APPROX. 429 ROOMS TO RISE IN A 1.4 HECTARE PRIME SITE AT SAN DONATO MILANESE, ABOUT A 7-MINUTE DRIVE TO THE MILAN LINATE AIRPORT HOTEL101-MILAN IS EXPECTED TO GENERATE EUR85.8 MILLION IN SALES REVENUE HOTEL101-MILAN IS SET TO BECOME THE SECOND HOTEL101 IN EUROPE, AND WITH ITS 1.4 HECTARE PRIME SITE AND APPROX. 429 ROOMS IS EXPECTED TO BE ONE OF THE TOP 3 LARGEST HOTELS IN THE METROPOLITAN CITY OF MILAN BY ROOMCOUNT(Site location of Hotel101-Milan, Italy set to have approx. 429 rooms) SINGAPORE, Nov. 29, 2025 (GLOBE NEWSWIRE) — Hotel101 Global Holdings Corp. (NASDAQ Ticker: HBNB) (“Hotel101” or “Hotel101 Global”), a leading asset-light, prop-tech hospitality platform pioneering a global standardized “condotel” business model listed on the Nasdaq Stock Exchange and a subsidiary of Philippine-listed...

CHENGDU, China, Nov. 28, 2025 (GLOBE NEWSWIRE) — Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the appointment of Mr. Jingkai Li as a director and the chairman of the board of directors (the “Board”), effective November 28, 2025. Mr. Li succeeds Ms. Hong Suong Nguyen, who has resigned from her positions as the chairperson and a director of the Board for personal reasons, effective on the same date. Mr. Li holds an executive master degree in business administration from Macau University of Science and Technology. His appointment reflects the Board’s confidence in his profound management expertise, forward-looking investment vision, and extensive background in the green industry. Over more than a decade leading Guangxi Qinyuan Environmental Protection Co., Ltd., he successfully built a technology-driven, cross-regional...

VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company and Odyssey Trust Company as the debenture trustee (the “Debenture Trustee”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the “Convertible Debentures“), holders (each, a “Debentureholder“) representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07 per Unit. The Company did not pay any cash finder’s fees pertaining to the Second Tranche of the Offering. The Company will use the proceeds of the Offering towards advancing its Alzheimer’s Disease (“AD”)...

SASKATOON, Saskatchewan, Nov. 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) today announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. “Paul’s appointment reinforces the continuity of our operating model and our confidence in his leadership,” said Alan Simpson, Executive Chairman of PharmaCorp. “His experience managing complex retail organizations and his steady execution...

EAST HANOVER, N.J., Nov. 28, 2025 (GLOBE NEWSWIRE) — Mondelēz Global LLC announced today a voluntary recall of 70 cases of RITZ Peanut Butter Cracker Sandwiches and sold in the following U.S. states: New York, New Jersey, Pennsylvania, Georgia, Arkansas, Missouri, Oklahoma, and Alabama. This recall is limited to 1 SKU and 2 Code Dates previously recalled in July. This action is not an expansion of that prior recall and is being conducted out of an abundance of caution. The affected cartons include individually wrapped packs that may be incorrectly labeled as Cheese variety even though the product may be a Peanut Butter variety. People who have an allergy or severe sensitivity to peanuts may risk serious or life-threatening allergic reactions by consuming this product. All outer cartons affected are labeled correctly and provide...

Toronto, Ontario, Nov. 28, 2025 (GLOBE NEWSWIRE) — Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) (“Ayurcann” or the “Company”) is excited to announce its financial and operational results for the three months ended September 30, 2025, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended September 30, 2025 and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.ayurcann.com and its profile page on SEDAR+ at www.sedarplus.ca. Q1 2026 Highlights: Consistent Execution Revenue: Ayurcann generated $14,638,697 in gross revenue, with gross profit of $2,236,343 and a healthy gross margin of 26% in Q1 2026 (vs. $14,657,485...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (“ERES” or “the REIT”) (TSX:ERE.UN) announced today that it has entered into agreements to sell three properties containing a total of 322 residential suites in the Netherlands for approximately €67.8 million in combined consideration. All amounts disclosed herein exclude transaction costs and other customary adjustments. Through certain of its subsidiaries, ERES has entered into separate agreements to sell:An unencumbered 33-suite property in Roermond for approximately €10.0 million; An unencumbered 88-suite property in Valkenburg for approximately €15.0 million; and A property containing 201 suites in Arnhem for approximately €42.8 million, with part of the proceeds to be used to repay approximately €15.2 million in associated mortgage...